Belite Bio Inc expected to post a loss of 37 cents a share - Earnings Preview
H.C. Wainwright starts coverage on Actuate Therapeutics with 'buy' rating
Brief: Belite Bio Announces Exercise Of Warrants For US$28.75 Million Gross Proceeds
Brief: Belite Bio Says Lead Pipeline, Tinlarebant Granted Sakigake Designation By Ministry Of Health, Labour & Welfare In Japan (MHLW) For Treatment Of STGD1.
Brief: Belite Bio Says Interim Data From "Dragon" Trial Expected In Q4 2024
Brief: Belite Bio Receives EMA Approval To Initiate Tinlarebant Phase 3 Clinical Trial
Brief: Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease
Brief: Belite Bio Announces Nmpa Submission For Tinlarebant Phase 3 Ga Clinical Trial In China
Brief: Belite Bio Reports Qtrly Net Loss Of $0.26 Per Share
Brief: Belite Bio Doses First Subject In Late-Stage Trial For Eye Disease
U.S. STOCKS ON THE MOVE-General Motors, Estee Lauder, IMAX
U.S. STOCKS ON THE MOVE-PaxMedica, Heron, Belite Bio
Belite Bio rises on enrollment completion in late-stage eye drug study
Brief: Belite Bio Completes Enrollment In Pivotal Global Phase 3 Dragon Trial Evaluating Oral Tinlarebant For Stargardt Disease
Brief: Belite Bio May Offer And Sell ADSs Having An Aggregate Offering Price Of Up To $100 Mln
U.S. STOCKS ON THE MOVE-Centerra Gold, gold miners, Travere Therapeutics
U.S. STOCKS ON THE MOVE-VerifyMe, Intel, Hewlett Packard Enterprise
Belite Bio tumbles on deep-discounted stock offering
U.S. STOCKS ON THE MOVE-Nvidia, Trevena, Akili